Double blinded, placebo-controlled trial of paliperidone addition in SRI [serotonin reuptake inhibitor]-resistant obsessive-compulsive disorder.

Trial Profile

Double blinded, placebo-controlled trial of paliperidone addition in SRI [serotonin reuptake inhibitor]-resistant obsessive-compulsive disorder.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Apr 2014

At a glance

  • Drugs Paliperidone (Primary)
  • Indications Obsessive-compulsive disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jun 2013 Primary endpoint 'Yale-Brown-Obsessive-Compulsive-Scale' has not been met.
    • 01 Jun 2013 Results published in the Journal of Clinical Psychiatry.
    • 01 Jun 2013 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top